Jendrike Nina, Eichenlaub Manuel, Link Manuela, Öter Sükrü, Beltzer Anne, Gil Miró Marta, Haug Cornelia, Seo Jung Hee, Kim Moon Hwan, Pleus Stefan, Freckmann Guido
Institut für Diabetes-Technologie, Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm, Ulm, Germany.
i-SENS, Inc., Seoul, Korea.
J Diabetes Sci Technol. 2025 Jul 3:19322968251351318. doi: 10.1177/19322968251351318.
The CE-marked CareSens Air continuous glucose monitoring (CGM) system (CSAir) features a 15-day sensor lifetime, a 2-hour warm-up period and mandatory manual calibrations. During subsequent product development, the algorithm was updated to reduce the warm-up period to 30 minutes and make user-entered calibrations optional. This study compared the CSAir's performance between the manual and updated algorithms.
Thirty adults with diabetes wore three CSAir sensors on their upper arms for 15 days. The study included three in-clinic sessions with capillary comparator measurements at 15-minute intervals over seven hours and glucose manipulation in the hypo- or hyperglycemic range. Point accuracy was assessed via mean absolute relative difference (MARD), 20/20 agreement rates (AR) stratified by BG range, and sensor wear time. Further evaluations included clinical point accuracy, alert reliability, technical reliability, safety and user satisfaction.
The CSAir's updated algorithm exhibited improved accuracy compared with the manual calibration algorithm, with a total 20/20 AR of 93.9% (vs 90.1%) and an MARD of 8.7% (vs 9.9%). Accuracy remained stable across measurement ranges and sensor lifetime. Diabetes Technology Society Error Grid analysis revealed high clinical accuracy, with 88.0% and 92.4% of data pairs in zone A for the manual and updated algorithms, respectively. The estimated survival probability was 88.8%. Participants reported positive user satisfaction. No safety concerns were identified.
Both algorithms of CSAir demonstrated robust performance and reliability with improved accuracy with the updated version. The study results of the CSAir suggest its suitability for nonadjunctive use.
具有CE标志的CareSens Air连续血糖监测(CGM)系统(CSAir)的传感器使用寿命为15天,预热期为2小时,且必须进行手动校准。在后续产品开发过程中,算法进行了更新,将预热期缩短至30分钟,并使用户输入校准变为可选操作。本研究比较了CSAir在手动算法和更新算法下的性能。
30名成年糖尿病患者在上臂佩戴三个CSAir传感器,为期15天。该研究包括三次门诊,每隔15分钟进行一次毛细血管对照测量,持续7小时,并在低血糖或高血糖范围内进行血糖调节。通过平均绝对相对差(MARD)、按血糖范围分层的20/20一致率(AR)以及传感器佩戴时间来评估点准确性。进一步评估包括临床点准确性、警报可靠性、技术可靠性、安全性和用户满意度。
与手动校准算法相比,CSAir的更新算法准确性有所提高,总20/20 AR为93.9%(相比之下为90.1%),MARD为8.7%(相比之下为9.9%)。在整个测量范围和传感器使用寿命内,准确性保持稳定。糖尿病技术协会误差网格分析显示临床准确性较高,手动算法和更新算法分别有88.0%和92.4%的数据对位于A区。估计生存概率为88.8%。参与者报告了积极的用户满意度。未发现安全问题。
CSAir的两种算法均表现出强大的性能和可靠性,更新版本的准确性有所提高。CSAir的研究结果表明其适用于非辅助使用。